Vernal Keratoconjunctivitis Market, by Drug Type (Bertilimumab, Verkazia, Lodoxamide, Tacrolimus, Antolimab, Nomacopan, and Others), by Treatment (Mast Cell Stabilizers, Antihistamines, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Topical Corticosteroid

Vernal Keratoconjunctivitis Market, by Drug Type (Bertilimumab, Verkazia, Lodoxamide, Tacrolimus, Antolimab, Nomacopan, and Others), by Treatment (Mast Cell Stabilizers, Antihistamines, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Topical Corticosteroids, Cyclosporine, Tacrolimus, and Others), by Dosage Form (Gel, Ointment, Tablet, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

The inner surface of the eyelid is lined with conjunctiva, a translucent tissue layer. When infected, this tissue tends to cover the white area of the eye and turn red or pink. As a result, the eye ailment conjunctivitis is often known as pink eye. The infection of the eye known as conjunctivitis is a common symptom of this ophthalmic condition. Infectious causes includes bacterial and viral infections, while non-infectious causes include allergy and immune-mediated illness inflammation. It is categorised into acute conjunctivitis, super acute conjunctivitis, and chronic conjunctivitis.

Vernal keratoconjunctivitis (VKC) is a chronic, multifactorial Th2-cell-mediated inflammatory disease of the ocular surface. It is distinguished by a large papilla on the upper tarsal conjunctiva and a corneoscleral junction. Hyperemia and mucus discharge are typical symptoms of VKC. There is no set standard treatment strategy for VKC. Mast cell stabilisers, antihistamines, nonsteroidal anti-inflammatory medications (NSAIDs), topical corticosteroids, and cyclosporine are available as treatments. Individuals receiving treatment should be continuously observed for the development of any ocular problems.
Market Dynamics
Increasing R&D activities in vernal keratoconjunctivitis for a better understanding of the disease is expected to drive the growth of global vernal keratoconjunctivitis market during the forecast period. In addition, increasing prevalence of vernal keratoconjuctivitis and supportive therapies have built the interest in several pharmaceutical companies in developing a cure for the disease. A greater knowledge of the disease's biology and manifestation of the disease has boosted efforts to develop improved treatment alternatives in the form of pipeline treatments, which is projected to propel the global vernal keratoconjunctivitis market share during the forecast period.
Key features of the study:
This report provides an in-depth analysis of the global vernal keratoconjunctivitis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global vernal keratoconjunctivitis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global vernal keratoconjunctivitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global vernal keratoconjunctivitis market
Detailed Segmentation:
Global Vernal Keratoconjunctivitis Market, By Drug Type :
Bertilimumab
Verkazia
Lodoxamide
Tacrolimus
Antolimab
Nomacopan
Others
Global Vernal Keratoconjunctivitis Market, By Treatment:
Mast Cell Stabilizers
Antihistamines
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Topical Corticosteroids
Cyclosporine
Tacrolimus
Others
Global Vernal Keratoconjunctivitis Market, By Dosage Form:
Gel
Ointment
Tablet
Others
Global Vernal Keratoconjunctivitis Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Vernal Keratoconjunctivitis Market, By Region:
North America
By Drug Type
Bertilimumab
Verkazia
Lodoxamide
Tacrolimus
Antolimab
Nomacopan
Others
By Treatment
Mast Cell Stabilizers
Antihistamines
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Topical Corticosteroids
Cyclosporine
Tacrolimus
Others
By Dosage Form
Gel
Ointment
Tablet
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Country
U.S.
Canada
Latin America
By Drug Type
Bertilimumab
Verkazia
Lodoxamide
Tacrolimus
Antolimab
Nomacopan
Others
By Treatment
Mast Cell Stabilizers
Antihistamines
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Topical Corticosteroids
Cyclosporine
Tacrolimus
Others
By Dosage Form
Gel
Ointment
Tablet
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type
Bertilimumab
Verkazia
Lodoxamide
Tacrolimus
Antolimab
Nomacopan
Others
By Treatment
Mast Cell Stabilizers
Antihistamines
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Topical Corticosteroids
Cyclosporine
Tacrolimus
Others
By Dosage Form
Gel
Ointment
Tablet
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type
Bertilimumab
Verkazia
Lodoxamide
Tacrolimus
Antolimab
Nomacopan
Others
By Treatment
Mast Cell Stabilizers
Antihistamines
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Topical Corticosteroids
Cyclosporine
Tacrolimus
Others
By Dosage Form
Gel
Ointment
Tablet
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Type
Bertilimumab
Verkazia
Lodoxamide
Tacrolimus
Antolimab
Nomacopan
Others
By Treatment
Mast Cell Stabilizers
Antihistamines
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Topical Corticosteroids
Cyclosporine
Tacrolimus
Others
By Dosage Form
Gel
Ointment
Tablet
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Country
GCC
Israel
Rest of Middle East
Africa
By Drug Type
Bertilimumab
Verkazia
Lodoxamide
Tacrolimus
Antolimab
Nomacopan
Others
By Treatment
Mast Cell Stabilizers
Antihistamines
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Topical Corticosteroids
Cyclosporine
Tacrolimus
Others
By Dosage Form
Gel
Ointment
Tablet
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Santen *
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Novartis Pharmaceuticals
Senju Pharmaceutical
Allakos
iCo Therapeutics
Akari Therapeutics
“*” marked represents similar segmentation in other categories in the respective section.